FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 57635

News■ Unclear/unknown

Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies

EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 14:31 UTC
LAST UPDATE2026-09-30 14:31 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A market forecast for vasomotor treatments is analyst projection, not evidence of near-term revenue.

Long-range forecast, minimal immediate impact
CATALYST TO WATCH

Trial readouts for emerging therapies

MAIN RISK

Forecasts often overstate adoption timelines

FULL DISPATCH

The vasomotor symptoms market is anticipated to increase during the forecast period (2026–2036), owing to improved diagnosis, treatment advancements, aging demographics, increased awareness, the launch of emerging therapies such as Cendifensine (NOE-115; Noema Pharma), Asimadoline (Tioga...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-09-30 14:31 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.